Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HTR7 | P34969 | 8/20 | 0.59 |
| ▸ | DRD2 | P14416 | 7/20 | 0.59 |
| ▸ | HTR6 | P50406 | 4/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532579 | 0.95 | KDM4E (0.60) | KDM4EGAAHTR7DRD2HTR6 | |
| SCHEMBL13532573 | 0.83 | KDM4E (0.64) | KDM4EHTR7DRD2HTR6HTR2A | |
| SCHEMBL14459608 | 0.81 | KDM4E (0.88) | KDM4EGAADRD2HTR2AHTR1A | |
| SCHEMBL16676579 | 0.80 | KDM4E (0.97) | KDM4EGAADRD2HTR2AHTR1A | |
| SCHEMBL20048037 | 0.79 | SMN1; SMN2 (0.56) | KDM4EHTR7DRD2HTR2AHTR1A | |
| Umespirone SCHEMBL678458 | 0.76 | DRD2 (0.69) | KDM4EHTR7DRD2HTR6HTR2A | |
| SCHEMBL10631261 | 0.75 | HTR1A (0.58) | HTR7DRD2HTR6HTR2AHTR1A | |
| SCHEMBL13079491 | 0.74 | KDM4E (0.78) | KDM4EGAADRD2HTR2AHTR1A | |
| SCHEMBL18754269 | 0.72 | KDM4E (0.75) | KDM4EGAADRD2HTR2AHTR1A | |
| SCHEMBL21802068 | 0.72 | HTR1A (0.80) | HTR7DRD2HTR6HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | KDM4E 3933/4885GAA 3419/4885HTR7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.